[A18-20] Emicizumab (haemophilia A) - Benefit assessment according to §35a Social Code Book V
Last updated 20.09.2018
Commission awarded on 27.03.2018 by the Federal Joint Committee (G-BA).
Routine prophylaxis of bleeding episodes in patients with haemophilia A with factor VIII inhibitors
Added benefit not proven due to lack of suitable study data
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A19-26||Emicizumab (haemophilia A) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A18-49||Emicizumab (haemophilia A) - Addendum to Commission A18-20||Commission completed|